Reversal of learned helplessness by morphine in rats: Involvement of a dopamine mediation

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 2, 1998, Pages 519-525

  Besson, A ^a   Privat, A M ^a   Eschalier, A ^a   Fialip, J ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Dopamine; Haloperidol; Learned helplessness; Morphine; Rats

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MORPHINE; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC SYSTEM; ESCAPE BEHAVIOR; HELPLESSNESS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; AVOIDANCE LEARNING; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; ELECTROSHOCK; ESCAPE REACTION; HALOPERIDOL; HELPLESSNESS, LEARNED; MALE; MORPHINE; NARCOTICS; RATS; RATS, WISTAR;

EID: 0032100463     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00002-1     Document Type: Article

References (52)

1. Abercrombie E.D., Keefe K.A., Di Frischia D.F., Zigmond M.J. Differential effects of stress on in vivo dopamine release in striatum, nucleus accumbens and medial frontal cortex. J. Neurochem. 52:1989;1655-1658.
2. Akil H., Watson S.J., Young E., Lewis M.E., Khachaturian H., Walker J.M. Endogenous opioids. Biology and function Annu. Rev. Neurosci. 7:1984;223-255.
3. American Psychiatry Association. DSM IV: Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Press; 1994:320-327.
4. Anisman H., Ritch M., Sklar L.S. Noradrenergic and dopaminergic interactions in escape behavior. Analysis of uncontrollable stress effects Psychopharmacology (Berlin). 74:1981;263-268.
5. Anisman H., Zacharko R.M. Multiple neurochemical and behavioral consequences of stressors. Implications for depression Pharmacol. Ther. 46:1990;119-136.
6. Berger A., Nemeroff C.B. Opioid peptides in affective disorders. Meltzer H.Y. The third generation of progress, Psychopharmacology, chapt. 63. 1987;637-646 Raven Press, New York.
7. Besson A., Privat A.M., Eschalier A., Fialip J. Effects of morphine, naloxone and their interaction in the learned helplessness paradigm in rats. Psychopharmacology (Berlin). 123:1996;71-78.
8. Borsini F., Lecci A., Macinell A., D'Aranno V., Meli A. Stimulation of dopamine D2 but not D1 receptors reduces immobility of rats in the forced swimming test. Implication for antidepressant activity. Eur. J. Pharmacol. 148:1988;301-307.
9. Briley M., Prost J.F., Moret C. Preclinical pharmacology of minalcipram. Intern. Clin. Psychopharmacol. 4:1996;9-14.
10. Brown A.S., Gershon S. Dopamine and depression. J. Neural Transm. Gen. Sec. 91:1993;75-109.
11. Cabib S., Oliverio A., Puglisi-Allegra S. Stress-induced decrease of 3-methoxytyramine in the nucleus accumbens of the mouse is prevented by naltrexone pretreatment. Life Sci. 45:1989;1031-1037.
12. Cabib S., Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharamcology (Berlin). 128:1996;231-342.
13. Cooper J.R., Bloom F.E., Roth R.H. The biochemical basis of neuropharmacology. 6:1991;Oxford University Press, New York. 285-337.
14. Di Chiara G., Alan North R. Neurobiology of opiate abuse. Trends Pharmacol. Sci. 13:1992;185-192.
15. Emrich H.M. A possible role of opioid substances in depression. Costa E., Racagni G. Typical and atypical antidepressants. Clinical practice, advances in biochemical psychopharmacology, vol. 32:1982;77-83 Raven Press, New York.
16. Geoffroy M., Christensen A.V. Psychomotor stimulants versus antidepressants in the learned helplessness model of depression. Drug Dev. Res. 29:1993;48-55.
17. Gessa G.L. Dysthymia and depressive disorders - Dopamine hypothesis. Eur. Psychiatry. 11(Suppl. 3):1996;S123-S127.
18. Gysling K., Wang R.Y. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res. 277:1983;119-127.
19. Harris J.C. Experimental animal modeling of depression and anxiety. Psychiatr. Clin. North Am. 12:1989;815-835.
20. 3H]DuP734, a novel sigma ligand. Brain Res. 598:1992;76-86.
21. Iyengar S., Dilworth V.M., Mick S.J., Contreras P.C., Monahan L.B., Rao T.S., Wood P.L. Sigma receptors modulate both A9 and A10 dopaminergic neurons in the rat brain. Functional interaction with NMDA receptors Brain Res. 524:1990;322-326.
22. Kalivas P.W., Abhold R. Enkephalin release into the ventral tegmental area in response to stress. Modulation of mesocorticolimbic dopamine Brain Res. 44:1987;339-348.
23. Katoh A., Nabeshima T., Kameyama T. Behavioral changes induced by stressful situations. Effects of enkaphalins, dynorphin, and their interaction J. Pharmacol. Exp. Ther. 253:1990;600-607.
24. Kendler K.S., Kessler R.C., Walters E.E., Mac Lean C., Neale M.C., Health A.C., Eaves L.J. Stressful life events, genetic liability, and onset of major depression in women. Am. J. Psychiatry. 152:1995;833-842.
25. Kitamura Y., Nagatami T. Buspirone enhances immobility in the forced swim test in mice. Pharmacol. Biochem. Behav. 55:1996;445-451.
26. Koob G.F. Drug of abuse. Anatomy, pharmacology and function of reward pathways Trends Pharmacol. Sci. 13:1992;177-184.
27. Largent B.L., Wilkstrom H., Gundlach A.L., Snyder S.H. Structural determinants of sigma receptor affinity. Mol. Pharmacol. 32:1987;772-784.
28. Leysen J.E., Janssen P.M., Gonmeren W., Wynants J., Pauwels P.J., Janssen P.A. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol. 41:1992;494-508.
29. Leyton M., Stewart J. Preexposure to footshock sensitizes the locomotor response to subsequent systemic morphine and intranucleus accumbens amphetamine. Pharmacol. Biochem. Behav. 37:1990;303-310.
30. Llorens-Cortes C., Pollard H., Schwartz J.C. Localization of opiate receptors in substantia nigra. Evidence by lesion studies Neurosci. Lett. 12:1979;321-326.
31. Magnus-Ellenbroek B., Havemann Reinecke U. Morphine-induced hyperactivity in rats. A rebound effect. Naunyn Schmiedebergs Arch. Pharmaco. 347:1993;635-642.
32. Maïer S.F., Seligman M.E.P. Learned helplessness. Theory and evidence J. Exp. Psychol. Gen. 1:1976;3-46.
33. Martin P., Soubrie P., Simon P. Noradrenergic and opioid mediation of tricyclic-induced reversal of escape deficits caused by inescapable shocks pretreatment in rats. Psychopharmacology (Berlin). 90:1986;90-94.
34. Martin P., Guillou N., Lacroix P., Billardon M. Effects of co-administration of anxiolytic and antidepressant drugs in the learned helplessness paradigm. Impact of hydroxyzine Encephale. 22:1996;270-279.
35. Mash D.C., Zabetian C.P. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse. 12:1992;195-205.
36. 2 and serotonin-2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265:1993;498-508.
37. Miller J.D., Speciale S.G., McMillen B.A., German D.C. Nalaxone antagonism of stress-induced augmentation of frontal cortex dopamine metabolism. Eur. J. Pharmacol. 98:1984;437-439.
38. 3H]NE-100 in guinea pig brain. Life Sci. 57:1995;33-337.
39. Overmier J.B., Seligman M.P. Effects of inescapable shocks upon subsequent escape and avoidance learning. J. Comp. Physiol. Psychol. 63:1967;23-33.
40. Petty F., Kramer G., Moeller M. Does learned helplessness induction by haloperidol involve serotonin mediation. Pharmacol. Biochem. Behav. 48:1994;671-676.
41. Raevskii K.S., Sotnikova T.D., Gainetdinov R.R. The brain dopaminergic systems. Receptor heterogeneity, functional role and pharmacological regulation Uspekhi Fiziologicheskikh Nauk. 27:1996;3-29.
42. Rosetti Z.L., Lai M., Hmadan Y., Gessa G.L. Depletion of mesolimbic dopamine during behavioral despair. Partial reversal by chronic imipramine Eur. J. Pharmacol. 243:1993;313-315.
43. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs. In vitro and in vivo receptor binding. Psychopharmacology (Berlin). 124:1996;57-73.
44. Shippenberg T.S., Bals-Kubik R., Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids. Role of the mesolimbic dopamine system and D1-vs D-2 dopamine receptors J. Pharmacol. Exp. Ther. 265:1992;53-59.
45. Su T.P., Schell S.E., Ford-Rice F.Y., London E.D. Correlation of inhibitory potencies of putative antagonists for sigma receptors in brain and spleen. Eur. J. Pharmacol. 148:1988;467-470.
46. Rejedor-Real P., Mico J.A., Maldonado R., Roques B.P., Gibert-Rahola J. Effects of mixed (Rb38a) and selective (Rb38b) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol. Psychiatry. 34:1993;100-107.
47. 3H] dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors. Schizophr. Res. 21:1996;51-62.
48. Willner P. Dopamine and depression. A review of recent evidence Brain Res. Rev. 6:1983;211-246.
49. Willner P. Validation criteria for animal models of human disorders. Learned helplessness as a paradigm case Prog. Neuropsychopharmacol. Biol. Psychiatry. 10:1986;677-690.
50. Willner P. Animal model as simulation of depression. Trends Neurosci. 121:1991;131-136.
51. Zacharko R.M., Anisman H. Stressor-induced anhedonia and the mesolimbic dopamine system. Neurosci. Biobehav. Rev. 15:1991;391-405.
52. Zacharko R.M., Bowers W.J., Kokkinidis L., Anisman H. Region specific reductions of intracranial self-stimulation after incontrollable stress. possible effects on reward processes Brain Res. 9:1983;129-141.